Merck & Co Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 03:40PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst

Welcome to the second day of the Bank of America Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. And we're thrilled today to have Merck on stage with us, and we have Caroline Litchfield. Caroline, welcome.

Caroline Litchfield - Merck & Co., Inc. - Executive VP & CFO

Thank you. Excited to be here and thanks for joining this session.

Questions and Answers:

Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst

It's great to do these in person now. I know we've all been pretty tired of Zoom. But let's talk sort of higher level. A lot of the questions on Merck that we've got, and I'm sure a lot of the ones you've gotten are your oncology business is very successful, but it's just grown in concentration. And today's sort of TIGIT news kind of shows that drug development is a risky business. But how are you thinking about that on the back of the Organon spin
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot